Form 4: Capricor Director Granted 15,500 Stock Options

Capricor Therapeutics director George W. Dunbar Jr. was granted 15,500 stock options with an exercise price of $24.81 for annual board service.

Summary

• George W. Dunbar Jr., a Director of Capricor Therapeutics, Inc. (CAPR), was granted 15,500 stock options.
• The transaction date for this grant was January 5, 2026.
• The exercise price for these stock options is $24.81 per share.
• The options will vest at a rate of 1/12th on the first day of each month, commencing February 1, 2026, with the final vesting on December 31, 2026.
• The expiration date for these options is January 5, 2036.
• The award is for annual board service.
• The option allows for early exercise, meaning all or any part can be exercised at any time.
• If early exercise occurs and the reporting person's service terminates prior to vesting, the purchased shares will be deemed restricted stock and subject to a repurchase option by the Issuer.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a standard compensation practice that aligns management interests with shareholders, generally viewed as a neutral to slightly positive event for corporate governance and long-term commitment.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• Equity compensation is a standard practice for attracting and retaining qualified board members.

Negatives

• The exercise of these options in the future could lead to a degree of share dilution for existing shareholders.

Risks

• If the reporting person elects to early exercise the options and purchases shares prior to vesting, these shares will be deemed restricted stock and subject to a repurchase option in favor of the Issuer if service terminates before vesting.

Future Outlook

The grant of these stock options indicates a continued commitment from the director to Capricor Therapeutics, with the vesting schedule extending through the end of 2026, aligning their long-term interests with the company's performance.

Industry Context

The grant of stock options to a director for annual board service is a common practice in the biotechnology and broader public company sectors. It serves as a key component of non-executive director compensation, aiming to align the director's incentives with shareholder value creation.

Comparison to Industry Standards

• Equity-based compensation, such as stock options, is a prevalent method for compensating non-employee directors across various industries, including biotechnology, to foster long-term commitment and align interests with shareholders.
• The vesting schedule over approximately one year is typical for annual grants, ensuring continued service for the vesting period.
• The inclusion of an early exercise feature, coupled with a repurchase option for unvested shares, is a common mechanism to provide flexibility while protecting the company's interests.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also increased alignment of director's interests with shareholder value.
• Employees: No direct impact mentioned in this filing.

Next Steps

• The stock options will begin vesting on February 1, 2026, continuing monthly until fully vested on December 31, 2026.
• The director may choose to exercise the options at any time, including prior to full vesting, subject to the repurchase option for unvested shares.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of stock options to a director as part of their annual compensation. While it signifies continued alignment of interests, it does not present new material information that would fundamentally alter the investment thesis or warrant a change in recommendation. It is a standard corporate governance event.

Keywords

Capricor Therapeutics, CAPR, Stock Options, Director Compensation, Equity Grant, Insider Transaction, Form 4, Biotechnology